This latest addition to the Methods in Molecular Medicine series, Anti- ral Methods and Protocols, is opportune because there is an increasing int- est in discovering compounds that are effective against both chronic and acute viral infections. A number of the methods described in the volume are unp- lished and their inclusion indicates the speed at which this field is moving. This volume is not a review but each chapter contains methods validated by the experts who have spent time in developing the protocols. The hallmark of this series is the comprehensive way in which the me- ods are described, which includes a list of all the reagents needed for each protocol. Of importance is the section on tips and pitfalls that the authors have discovered while developing their protocols. The manual itself is designed to be used by researchers in universities and industry who are familiar with a range of biological techniques but who want to set up quickly a novel assay system. We encourage a dialog between readers and authors, which may also result in useful collaborations.

Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices covers the modern micro and nanotechnologies used for diagnosis, drug delivery, and theranostics using micro, nano, and implantable systems. In-depth coverage of all aspects of disease treatment is included. In addition, the book covers cutting-edge research and technology that will help readers gain knowledge of novel approaches and their applications to improve drug/agent specificity for diagnosis and efficient disease treatment. It is a comprehensive guide for medical specialists, the pharmaceutical-industry, and academic researchers discussing the impact of nanotechnology on diagnosis, drug delivery, and theranostics.

This book contains contributions presented at the last of the Alcuin Symposia, held in April 2000, as a Festschrift to honour Prof. Axel Wollmer on the occasion of his retirement from the Rheinisch-Westfalische Technische Hochschule (RWTH) Aachen. The Alcuin Symposia were initially held alternatively in York and Aachen, in recent years in Aachen only, as joint workshops on insulin between the groups of Prof. Guy Dodson in York and the groups of Profs Dietrich Brandenburg and Axel Wollmer in Aachen. The Symposium was named after Alcuin, an Anglo-Latin poet, educator and cleric from York, who was invited to join the court of Charlemagne at Aachen. Alcuin's first 50 years were spent in Yorkshire, were he was first a pupil, later headmaster of the cathedral school of York, the most renowned of its day. Charlemagne was gathering at Aachen the leading Irish, English and Italian scholars of the age. Alcuin was appointed head of the Palatine school, where Charlemagne himself, his family, his friends, and his friends's sons were taught. Alcuin introduced the traditions of Anglo-Saxon humanism into Western Europe and was the foremost scholar of the revival of learning known as the Carolingian Renaissance. He also promoted the use of the beautiful Carolingian minuscule script, the ancestor of modern Roman typefaces."

Daydreaming, our ability to give 'to airy nothing a local habitation and a name', remains one of the least understood aspects of human behaviour. As children we explore beyond the boundaries of our experience by projecting ourselves into the mysterious worlds outside our reach. As adolescents and adults we transcend frustration by dreams of achievement or escape, and use daydreaming as a way out of intolerable situations and to help survive boredom, drudgery or routine. In old age we turn back to happier memories as a relief from loneliness or frailty, or wistfully daydream about what we would do if we had our time over again. Why is it that we have the ability to alternate between fantasy and reality? Is it possible to have ambition or the ability to experiment, create or invent without the catalyst of fantasy? Are sexual fantasies an inherent part of human behaviour? Are they universal, healthy, destructive? Is daydreaming itself destructive? Or is it a force which facilitates change and which can even be harnessed to positive advantage? In this provocative book, originally published in 1975, the product of the previous twenty-five years of research, the author debates the nature and function of daydreaming in the light of his own experiments. As well as investigating what is a normal 'fantasy-life' and outlining patterns and types of daydreaming, he describes the role of daydreaming in schizophrenia and paranoia, examines the fantasies and hallucinations induced by drugs and also the nature of altered states of consciousness in Zen and Transcendental Meditation. Among the many topics covered, he explains how it is possible to help children enlarge their capacity for fantasy, how adults can make positive use of daydreaming and how people on the verge of disturbed behaviour are often unconscious of their own fantasies. Advances in scientific methods and new experimental techniques had made it possible at this time to monitor both conscious daydreaming and sub-conscious fantasies in a way not possible before. Professor Singer is one of the few scientists who have conducted substantial research in this area and it is his belief that the study of daydreaming and fantasy is of great importance if we are to understand the workings of the human mind.

Natural Products in Vector-Borne Disease Management explores the potential application of natural products in vector control and disease management. The chapters discuss the global impact of specific vector-borne diseases, gaps in management, and natural products in specific stages of development - discovery, optimization, validation, and preclinical/clinical development. Toxic effects and mechanisms of action are also discussed. This book also explores how therapeutic plant derivatives can be used to combat the vectors of infection and how natural products can be used to manage and treat vector-borne diseases like malaria, leishmaniasis, dengue, and trypanosomiasis. With the inclusion of case studies on field and clinical applications and the contributions from experts in the field, Natural Products in Vector-Borne Disease Management is an essential resource to researchers, academics, and clinicians in parasitology, virology, microbiology, biotechnology, pharmacology, and pharmacognosy working in the field of vector-borne diseases.

This book details current developments in all natural polymers, with a focus on animal and microbial polysaccharides. The book examines, compares, and contrasts the efficiency of plant and algae based natural polymers in inducing immune reactions. Additionally, the book details the safety and toxicity profiles with respective regulations.

Aerosol therapy has significantly improved the treatment of a variety of respiratory diseases. Besides the treatment of respiratory diseases there is currently also a great interest to use the lungs as a portal to introduce drugs for systemic therapy.
The success of therapy with the application of aerosolized medicaments depends on the possibility to deliver the proper amount of drug to the appropriate sites in the respiratory system, thus limiting the side effects to a minimum. Aerosolized delivery of drugs to the lung is optimized if, for a given chemical composition of a medicine, the target of deposition and the required mass of drug to be deposited are precisely defined.
The next step is the specification of the number of respirable particles or droplets, to be generated by appropriate devices. Another very important factor for successful aerosol therapy is the condition of the patient coupled with his or her inhalation technique.

We are now on the verge of viewing effector molecules and other regulatory sites as therapeutic targets for the amelioration of human and animal disease. The recognition, for example, that mutant proteins are frequently misrouted molecules, rather than functionally defective ones, changes our approach to "inborn errors of metabolism" and offers new approaches for pharmacological discovery, based on rescue of receptors, ion channels and enzymes with pharmacoperones. Ion channels, regulators of G-protein signaling and enzymes engaged in regulation, now present opportunities for drug development.

The state of our art also benefits by the availability of superior tools that allow measurement of interactions and afford unprecedented insight into the biomolecular interactions that present novel approaches to drug design.

"Mycobacterium tuberculosis" is one of the most notorious pathogens on earth, causing the death of approximately 1.5 million people annually. A major problem in the fight against tuberculosis is the emergence of strains that have acquired resistance to all available antibiotics. One key to the success of "M. tuberculosis" as a pathogen is its ability to circumvent host immune responses at different levels. This is not only a result of the special makeup of "M. tuberculosis" in terms of genetic diversity and DNA metabolism and its possession of specialized secretion systems, but also of its ability to hijack the host s innate immune defence mechanisms.

In this volume, researchers from different disciplines provide a topical overview of the diverse mechanisms that contribute to the virulence of "M. tuberculosis," ranging from their genetic, metabolic and molecular makeup, as well as the complex strategies these bacteria utilize to escape immune destruction within infected hosts."

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers.

Liquid-Chromatography-Mass-Spectrometry procedures have been shown to be successful when applied to drug development and analysis. LC-MS in Drug Analysis: Methods and Protocols provides detailed LC-MS/MS procedures for the analysis of several compounds of clinical significance. The first chapters provide the reader with an overview of mass spectroscopy, its place in clinical practice, its application of MS to TDM and toxicology, and the merits of LC-MS(/MS) and new sample preparation techniques. The following chapters discuss different approaches to screening for drugs of abuse and for general unknowns, as well as targeted measurement of specific analytes or classes of analytes including abused drugs, toxic compounds, and therapeutic agents. Written in the successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible protocols, and notes on troubleshooting and avoiding known pitfalls. Authoritative and easily accessible, LC-MS in Drug Analysis: Methods and Protocols seeks to serve both professionals and novices with its well-honed methodologies.

Disease-relevant intracellular protein-protein interactions occurring at defined cellular sites possess great potential as drug targets. They permit highly specific pharmacological interference with defined cellular functions. Drugs targeting such interactions are likely to act with fewer side effects than conventional medication influencing whole cell functions.

This book discusses therapeutically relevant protein-protein interactions with a major focus on scaffolding proteins tethering signal transduction processes to defined cellular compartments by direct protein-protein interactions. Recent advances in the development of pharmacological agents interfering with protein-protein interactions are highlighted.

Bioinformatics and Drug Discovery describes the bioinformatic approaches and techniques employed along the pipeline of drug development from genes to proteins to drugs. The book focuses on gene microarray analysis and techniques for target identification and validation. In addition, clinical applications showing how the analysis can be used for prognostication and diagnosis are described. The second section focuses on protein analysis, including target validation and identification using modern proteomic analysis as well as protein modeling techniques. The third section discusses chemoinformatics, including virtual screening and how to computationally approach chemical space.

The 2022 edition of the Rules and Guidance for Pharmaceutical Distributors, the 'Green Guide', is the essential reference for all distributors, brokers of human medicines, importers and distributors of active substances in the UK.It provides you with the single authoritative source of European good distribution practices and UK guidance, information and UK legislation on these activities.The new 5th edition has been updated to incorporate changes made after the UK's exit from the European Union on the 31st January 2020.It also incorporates new guidance on pharmacovigilance for wholesalers, the naming of sites on a licence, self-inspection, and the responsible person for import.It brings together EU guidance on good distribution practice and the MHRA's expectations for compliance. There is also a new flowchart for the registration of handling active substances

Product information not available.

The last decade or so has seen remarkable advances in our knowledge of cough. This applies especially to its basic mechanisms: the types of airway sensors, the phar- cological receptors on their membranes, the brainstem organization of the 'cough centre', and the involvement of the cerebral cortex in the sensations and the vol- tary control of cough. With the exception of the last of these, nearly all the studies have been on experimental animals rather than humans, for obvious reasons. One group of experimental studies has particular relevance to human patients, and that is the demonstration of the sensitization of cough pathways both in the periphery and in the brainstem. Similar sensitizations have been shown for patients with chronic cough or who have been exposed to pollutants, and it is reasonable to suppose that this is the basis of their cough and that the underlying mechanisms are generally similar in humans and other species. Important advances are also being made in clinical cough research. For the three main causes of clinical cough, asthma, post-nasal drip syndrome, and gast- oesophageal re?ux disease, we are beginning to understand the pathological processes involved. There remains a diagnostically obdurate group of idiopathic chronic coughers, but even for them approaches are being devised to clarify und- lying mechanisms and to establish diagnoses. Perhaps surprisingly, the ?eld in which there has been the least spectacular - vance is the therapy of cough.

This volume describes recent research in the field of metalloproteinas es, in particular their participation in autoimmune diseases such as r heumatoid arthritis. The work updates current progress in matrix metal loproteinase research, reviewing the latest developments in metallopro teinase inhibitor design and the current status of clinical candidates . It elucidates the structural relationships between different members of the MMP family and provides insight into the contributions of diff erent metalloproteinases to normal and pathological processes. Special emphasis is given to the potential of adamlysins as therapeutic targe ts. This volume is intended not only for those active in research into metalloproteinases but also for those with an interest in inflammator y diseases. Thus it addresses both academic and industrial researchers .

This book provides a comprehensive overview of chitin biology and chitin metabolism related enzymes. Chitin, the second most abundant biopolymer in nature after to cellulose, is a linear biopolymer composed of -1,4-linked N-acetylglucosamine (GlcNAc), and an essential component in the exoskeletons of insects, mites, ticks and crustaceans, the egg shells of parasitic nematodes, and fungal cell walls. Although some chitin-containing organisms are a threat to human health, food safety and agricultural production, non-chitin containing organisms like humans, mammals and plants have an innate immune response to these hazardous organisms. The book provides researchers and students with information on the recent research advances concerning the biology of chitin-containing organisms as well as cross-talks between chitin-containing and non-chitin-containing organisms. Highlighting chitin remodeling enzymes and inhibitors, it also offers drug developers essential insights into designing specific molecules for the control of hazardous chitin-containing organisms.